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Liver mortality among individuals with chronic hepatitis C (CHC) infection is common, but the relative contribution of 
CHC per se versus adverse health behaviours is uncertain. We explored data on spontaneous resolvers of hepatitis C 
virus (HCV) as a benchmark group, to uncover the independent contribution of CHC on liver mortality. Using national 
HCV diagnosis and mortality registers from Denmark and Scotland, we calculated the liver mortality rate (LMR) for 
persons diagnosed with CHC infection (LMRchronic) and spontaneously resolved infection (LMRresolved), according to 
subgroups defined by: age; gender; and drug use. Through these mortality rates we determined subgroup-specific 
attributable fractions (AFs), defined as (LMRchronic – LMRresolved)/LMRchronic. , and then calculated the Total Attributable 
Fraction (TAF) as a weighted average of these AFs. Thus, the TAF represents the overall fraction (where 0.00=not 
attributable at all; and 1.00=entirely attributable) of liver mortality attributable to CHC in the diagnosed population. 
Our cohort comprised 7005, and 21729 persons diagnosed with HCV antibodies in Denmark and Scotland, respectively. 
The mean follow up duration was 6.3-6.9 years. The TAF increased stepwise with age. It was lowest for death occurring 
at <45 years of age (0.21 in Denmark; 0.26 in Scotland); higher for death occurring 45-59years (0.69 in Denmark; 0.69 
in Scotland) and highest for death at 60+years (0.92 in Denmark; 0.75 in Scotland). Overall, the TAF was 0.66 
(95%:0.55-0.78) in Denmark and 0.55 (95%CI: 0.44-0.66) in Scotland. Conclusion: In Denmark and Scotland, the 
majority of liver death in the CHC-diagnosed population can be attributed to CHC- nevertheless, an appreciable fraction 
cannot, cautioning that liver mortality in this population is a compound problem that can be reduced but not solved 











Persons with Chronic Hepatitis C (CHC) infection exhibit rates of liver mortality that are between 17 and 36 times 
greater than the general population[1-6]. A prerequisite to an effective public-health response, is a complete 
understanding of the factors driving this phenomenon. Although CHC is an established cause of liver failure and liver 
cancer, we cannot assume that all liver deaths occurring in the CHC infected population are de-facto attributable to 
CHC. To judge the CHC contribution, we need to uncover the benchmark mortality rate; in other words, the rate of liver 
mortality that this population would exhibit in the absence of CHC. This is a challenging task; CHC infection is 
inextricably linked to high rates of: injecting drug use (IDU)[7-9], alcohol use disorders (AUDs) [9-14], psychiatric 
comorbidities [9,11] and polysubstance abuse [15]. Epidemiologically, it is hard to disentangle liver mortality 
attributable to CHC, from liver mortality that might have occurred anyway given competing risk factors.  
A potentially misprized benchmark group, overlooked until now, are spontaneous resolvers. The natural history of 
infection is such that, upon exposure to the virus, three-quarters of individuals develop persisting chronic infection that 
is clearable only through antiviral treatment [16]. But the remaining quarter resolve the infection spontaneously (i.e. of 
their own accord) within a matter of weeks to months [17]. Resolvers, by virtue of being exposed to HCV at all, are 
likely to be broadly similar to their chronic counterparts in terms of lifestyle exposures. In this sense then, resolvers may 
serve as a useful yardstick from which to assess the independent contribution of CHC. With these thoughts in mind, a 
joint research initiative between Denmark and Scotland was established. To our knowledge, we are the only two 
countries in the developed world: (i) with a national HCV diagnosis database capable of distinguishing persons 
diagnosed with HCV antibodies according to their chronic versus resolved infection status, and (ii) where those 
databases are linked routinely to subsequent mortality data. Using these unique data, our aim was to examine the extent 









STUDY DESIGN AND SETTING: 
We performed a record linkage analysis utilising HCV diagnosis, hospitalisation and mortality registers in two distinct 
settings – Denmark and Scotland. Both are Northern European countries with ~5.5 million inhabitants. The estimated 
prevalence of CHC infection is ~0.4% in Denmark [18] (equivalent to ~17,000 individuals) and ~0.8% in Scotland [19] 
(~39,000 individuals). In both settings, the principal transmission route is IDU [7, 20].  In Denmark, ~0.5% of persons 
living with CHC receive antiviral therapy each year [21], whereas in Scotland, treatment uptake is higher at 2.5-3% 
[19]. Official population statistics on alcohol use and related sequalae suggest historically higher consumption levels in 
Denmark than in Scotland; albeit, differences have diminished over the last decade (see eFig.1).  
 
DATA SOURCES: 
Denmark: HCV infected patients were identified from the Danish HCV diagnosis database (known as DANVIR), 
comprising all persons tested for HCV in 14 of the 18 laboratories that perform such testing in Denmark [6]. DANVIR 
data include results and dates of HCV antibody tests (from 1991 onward) and HCV RNA tests (from 1995 onward). 
Data on the vital status of all Danish citizens, including date of death or emigration, is stored by the Civil Registration 
System [22]. The Danish National Registry of Causes of Death contains information on date and causes of death on all 
deceased Danish citizens [23]. The Danish National Patient Registry (DNPR), established in 1977, collects information 
on all non-psychiatric hospital admissions in Denmark, and since 1995, outpatient and emergency department visits 
moreover. Data linkage between DANVIR and:  (i) the Civil Registration System; (ii) the Danish National Registry of 
Causes of Death; and (iii) the DNPR, was performed through deterministic matching of the unique 10-digit civil 




Scotland: HCV infected individuals were identified through the Scottish HCV diagnosis database, which records all 
new anti-HCV positive diagnoses in Scotland from 1991 onwards [1]. Scotland also holds a national database for: (i) all 
general and acute inpatient/day case hospital admissions (known as the SMR-01 database); (ii) all mental health 
inpatient/day case admissions (known as the SMR-04 database); and (iii) all deaths [24]. The HCV diagnosis database 
was linked to these three registries through a two-step process. Using the full set of patient identifiers held on the HCV 
diagnosis (forename initial, surname soundex, date of birth, gender, postcode sector), an intermediary linkage to the 
Community Health Index (CHI) database was performed to obtain the “CHI number” (step 1). The CHI number is a 
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unique individual–specific number allocated to every person upon registration with a general practitioner in Scotland; it 
functions as a master index for linkage between population registries in Scotland and is equivalent to the 
aforementioned Danish civil-registration number. Knowledge of the CHI number therefore enabled retrieval of each 
HCV diagnosed patient’s records from the SMR-01, SMR-04, and mortality databases (step 2). These linkages were 
performed by Information Services Division Scotland, after approval from National Services Scotland Privacy Advisory 
Committee. 
 
INCLUSION AND EXCLUSION CRITERIA: 
The inclusion criteria was receipt of a first-time diagnosis for HCV antibodies from the year comprehensive PCR 
testing was introduced (1995 in Denmark and 1996 in Scotland) until the year diagnosis data were complete to (2007 in 
Denmark and 2012 in Scotland). A total of 11,977 Danish persons, and 30,049 Scottish persons met these initial 
inclusion criteria. After applying appropriate exclusions (mainly for missing data on HCV infection status; and for 
Scotland, also for not linking to the CHI database, see eFig.2), our final analysis featured 7,005 and 21,729 individuals 
from Denmark and Scotland, respectively. 
 
EXPOSURE VARIABLES 
The primary exposure variable was chronic versus spontaneous resolved HCV infection inferred from the first 
determinate HCV RNA test conducted following or simultaneous to the diagnosis of HCV antibodies. Specifically, a 
first test with a positive HCV RNA result was taken to indicate chronic infection, whilst a first test with a negative 
result was taken to indicate spontaneous resolution. In Scotland, trained data entry staff with access to full PCR test 
history apply this definition manually to all patient records. In contrast, for Denmark where all RNA tests are recorded 
and stored within DANVIR itself, this definition was applied electronically. We also characterised individuals in terms 
of IDU history. For Denmark, IDU was defined as inclusion in the Registry of Drug Abusers Undergoing Treatment 
and/or a record of one or more diagnoses suggesting IDU in the DNRP (Appendix A). For Scotland, a history of IDU 
was based on risk information disclosed by the patient at the time of the HCV test.  
 
OUTCOME VARIABLE 
Liver mortality was the primary outcome. This was defined using the underlying (i.e. primary) cause of death, specified 
by the followingICD-9 and ICD-10 codes: primary liver cancer (ICD-10 C22; ICD-9 155); alcoholic liver disease (ICD-
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10 K70;ICD-9 571.0-571.3); non-alcoholic liver disease (ICD-10 K71-77; ICD-9 570, 571.4-571.9, 572-573); viral 
hepatitis (ICD-10 B15-19; ICD-9 070); and sequelae of viral hepatitis (ICD-10 B94.2; R18; I850; ICD-9 456.0, 789.5). 
 
STATISTICAL ANALYSIS: 
To avoid breaching patient confidentiality safeguards, Danish and Scottish linkage data were analysed separately, by 
different authors (LO and HI), but according to a single standardised protocol. The main analysis was to determine the 
fraction of liver death in the CHC diagnosed population that is attributable to CHC (i.e. that would not have occurred if 
CHC had not been present). We further carried out an auxiliary analysis, and a one-way sensitivity analysis to support 
interpretation of the main analysis – as follows:  
 
(i) MAIN ANALYSIS: FRACTION OF LIVER DEATH ATTRIBUTABLE TO CHC  
For subgroups defined by current age group (<45 years; 45-59 years; and 60+ years), gender (male versus female) and 
IDU history (known history versus no known history), we determined the liver mortality rate (LMR) for patients with 
chronic (LMRchronic) and resolved (LMRresolved) HCV infection. The LMR for each subgroup was calculated by dividing 
the aggregate number of liver deaths, by the aggregate time at risk. For each individual, time at risk (expressed in 
person-years) began 180 days after HCV diagnosis (as is standard
 
[1,2, 4-6]), and was censored either at occurrence of 
non-liver mortality, or at the date national mortality cdata was complete until (31 Dec 2009 in Denmark and 31 Dec 
2013 in Scotland). We calculated the attributable fraction (AF) for each subgroup, defined as (LMRchronic – 
LMRresolved)/LMRchronic. Where LMRresolved  exceeded LMRchronic, we took the AF in that subgroup to be zero. AFs 
indicates the fraction of liver death attributable to CHC (i.e 0.00=not attributable at all; 0.5=equally attributable and 
non-attributable; 1.00=entirely attributable). The indicative number of liver deaths attributable to CHC was determined 
by multiplying the subgroup-specific AF by the number of liver deaths occurring with CHC infection in that same 
subgroup. To derive the total attributable fraction (TAF), we divided the indicative total number of liver deaths 
attributable to CHC by the total liver deaths occurring with CHC infection. The TAF thus, is effectively a weighted 
average of subgroup-specific AFs; and it is interpretable as an estimate of the fraction of liver mortality attributable to 
CHC in the diagnosed population. We used a bootstrapping approach to quantify imprecision in all our estimates. From 
our original cohort, we sampled with replacement to generate 10,000 bootstrap samples, each with the same number of 





 percentile in the resulting distribution to indicate the range of values consistent with our data. 
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(ii) AUXILIARY ANALYSIS: ADVERSE HEALTH BEHAVIOURS ACCORDING TO HCV INFECTION 
STATUS 
We used Cox regression to determine the association between HCV infection status, and the time to first hospitalisation 
for a suite of admissions that reflect adverse health behaviours. As per our main analysis, we commenced follow-up 180 
days after HCV diagnosis, and censored follow-up for mortality or for reaching the date that national hospitalisation 
data were complete until (31 Dec 2009 for Denmark; 31 Dec 2013 for Scotland). Three events were considered: 1) 
hospitalisation for an acute instance of drug intoxication; 2) hospitalisation for an acute instance of alcohol intoxication; 
and 3) hospitalisation for injury incurred through violence (although N.B, violence-related injury could not be assessed 
as a behavioural outcome in Denmark because this outcome is recorded in a separate registry that we did not have 
access to for this study [25]).ICD codes were used to define all events; see eTable 1. We calculated the hazard ratio for 
each event, according to chronic infection versus spontaneous resolved infection, after adjustment for age group, gender 
and known history of IDU.  
(iii) SENSITIVITY ANALYSIS: ACCOUNTING FOR THE IMPACT OF ANTIVIRAL THERAPY 
Data on commencement of antiviral therapy is available in Scotland through a national HCV clinical database 
(described previously elsewhere: [26]). To gauge the influence of treatment on our principal conclusions, we repeated 
our main analysis, but this time, further censored follow-up at the date of treatment initiation (if the treatment episode in 
question, gave rise to attainment of SVR by April 2013).To note, the same sensitivity analysis was not performed in 
Denmark because linkage to the Danish clinical database (known as DANHEP), had not been conducted at the time of 











DESCRIPTION OF COHORT:  
This analysis included 7,005 persons diagnosed with HCV antibodies in Denmark and 21,729 likewise persons from 
Scotland. Individuals in the Danish cohort, on average, were older than those in Scotland (mean age at diagnosis: 39.7 
years in Denmark, versus 35.3 years in Scotland). In both settings, males outnumbered females (~2:1 ratio), and a 
similar proportion reported a history of IDU (50-60%). The fraction of individuals with resolved HCV infection versus 
chronic infection was higher in Denmark (37.6%) than in Scotland (20.3%). Consistently in both settings, resolvers 
were younger than those with chronic infection (on average, by 1.3-1.5 years), and were more commonly female; see 
Table 1. 
FOLLOW-UP TIME AND LIVER MORTALITY: 
The total duration of follow-up in Denmark was 46,134 person-years; equating to a median per patient observation of 
6.34 years (see eTable 2). Over this observation period, 1206 individuals died, and 247 (20.5%) of these deaths were 
liver-related (equating to a crude rate of 53.5 liver deaths per 10,000 person-years). In Scotland, total follow-up was 
162,607 person-years; equating to a median of 6.93 years per patient. Over this duration, 2898 individuals died, with 
729 (25.2%) of these deaths being liver-related (crude rate:44.8 liver deaths per 10,000 person-years). In both settings, 
the type of liver death differed according to the HCV infection status of the decedent; see eFig.3. Most deaths among 
resolvers were due to alcoholic liver disease (i.e. in >2/3
rds
 of instances), with a minimal contribution from liver cancer 
(<6%). A different picture was apparent for those with chronic infection; alcoholic liver disease was less frequently 
indicated (in <50% of deaths), whilst more than a fifth of liver mortality was attributed to hepatocellular carcinoma 
(21.5-21.6%).  
MAIN ANALYSIS: FRACTION OF LIVER DEATH ATTRIBUTABLE TO CHC INFECTION 
The TAF was 0.66 (95%:0.57-0.79) in Denmark and 0.55 (95%CI: 0.44-0.66) in Scotland- but it varied according to the 
age at death (see Fig.1). The TAF was low for death occurring at <45 years of age; 0.21 (95% CI: 0.11-0.63) in 
Denmark and 0.26 (95% CI: 0.07-0.47) in Scotland. The TAF was moderate/high for death occurring at 45-59 years of 
age; 0.69 (95% CI: 0.52-0.82) in Denmark and 0.69 (95% CI: 0.53-0.83) in Scotland. The TAF was highest for deaths at 




AUXILIARY ANALYSIS: ADVERSE HEALTH BEHAVIOURS ACCORDING TO HCV INFECTION STATUS 
CHC infection status (relative to spontaneous resolution) was not associated with a decreased risk of hospitalisation for 
adverse health behaviours after adjustment for age, gender and IDU history. There was some indication to the contrary 
however; In Denmark, CHC infection was associated with a significantly increased risk of hospitalisation drug 
intoxication (adjusted hazard ratio: 1.25, 95%CI: 1.06-1.49); see Table 3. 
SENSITIVITY ANALYSIS: ACCOUNTING FOR THE IMPACT OF ANTIVIRAL THERAPY 
In Scotland, during the course of follow-up, 5059 individuals with CHC were treated with antiviral therapy and, 2436 
attained SVR. We note that 94 spontaneous resolvers were also listed as having received a course of treatment during 
follow-up - we discuss this observation in our limitations section. When censoring follow-up time at SVR attainment, 




















Rates of liver mortality are high among persons with CHC [1-6]. An effective public-health response to this 
phenomenon must reflect the causes behind these excess deaths.  In this study, we use spontaneous resolvers as a 
benchmark group, to judge the independent contribution of CHC. Our findings indicate that in Scotland, 55% (95% CI: 
44-66) of liver death among CHC-infected individuals can be attributed to the CHC exposure. In Denmark, this fraction 
is higher at 66% (95% CI: 55-78). On the one hand, these results support the consensus view – that the majority of liver 
death in this population is attributable to the CHC exposure. At the same time, they also show that a not insignificant 
portion of liver mortality appears to occur independently of infection; there are two immediate corollaries of this. 
Firstly, although attempts to curtail liver mortality in this population rest mainly on the provision of antiviral therapy, 
antivirals alone may not be sufficient to eradicate the liver mortality problem. Secondly, if a baseline risk of liver 
disease among persons who acquire HCV exists, then we must ensure that this is fairly incorporated into modelling 
work. Existing cost-effectiveness [27-30], population forecasting [31-33], and patient prognosis models [34] tend to 
assume negligible disease progression in the absence of chronic infection; this assumption will likely bias results in 
favour of treatment and may give rise to inflated drug costs.  
 
VALIDITY OF USING SPONTANEOUS RESOLVERS AS A BENCHMARK GROUP 
Using spontaneous resolvers as a control group to gauge the independent contribution of CHC is a novel idea.Resolvers, 
by virtue of having been exposed to HCV at all, are likely to be broadly similar to their chronic counterparts in terms of 
adverse health behaviours (behaviours that are otherwise difficult to measure precisely[35.36] but which may influence 
liver disease progression appreciably).This assumption of similarity betweeen chronics and resolvers in terms of 
adverse health behaviours is supported by studies examining the determinants of spontaneous resolution [37-40]. We 
further performed an auxillary analysis to assess the ongoing risk of hospitalisation for acute alcohol intoxication, acute 
drug intoxication and hospitalisation for violence-related injury (i.e.admissions that reflect ongoing adverse health 
behaviors). We found similar admission risks according to infection status with the exception of a small increased risk 
of drug intoxication in Danish chronics versus Danish resolvers (HR 1.25; 95% CI: 1.06-1.49). However a limitation of 
this auxiliary analysis is that it only considers the relationship between infection status and extreme health behaviours. 
In other words, the results may not generalise to moderately adverse- but harmful nonetheless – health behaviours. 
Spontaneous resolvers differ from chronically infected persons demographically (are more commonly younger and of 
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female gender [17]), and genetically (in terms of single nucleotide polymorphisms in the vicinity of the IL28B gene 
[41]). Our analyses are adjusted for age and gender, but not for any genetic differences between these two groups that 
may govern immune system response. This is an important limitation because it might undervalue the risk that CHC 
poses; recent studies have shown that among individuals with CHC, polymorphisms favouring spontaneous resolution 
may be associated with hepatic decompensation [42]. It is possible that these polymorphisms could hasten liver disease 
progression from other aetiologies [43], meaning that paradoxically, individuals who spontaneously resolve HCV may 
be more susceptible (in a genetic sense) to liver disease, than those who progress to chronic infection. Nevertheless, the 
picture is very preliminary- the potential for bias here should be reviewed as new data emerges. A further implicit 
assumption of this analysis is that the duration for which spontaneous resolvers harbour viral RNA (median of 16.6 
weeks [17]) is sufficiently short to preclude the virus causing any significant liver damage. Very occasionally, 
spontaneous resolution occurs much later [44], and in these instances, the potential for HCV-induced liver damage will 
be greater.  
 
FURTHER LIMITATIONS AND CAVEATS 
Our definition of spontaneous resolution is based on the very first PCR test result conducted after or at the time of 
antibody detection. This should offer a robust indication of chronic versus resolved infection given the established 
serological timeline of infection [45]. However, this definition has two caveats. First some individuals will have gone 
on clear their chronic infection through antiviral therapy during the course of follow-up. This switch from chronic to 
cleared chronic is not accounted for in our base case analysis, For two reasons though, this is unlikely to impact our 
results: (A) at the population level, the impact of antiviral therapy on liver mortality is known to have been minimal, 
owing in part to poor response rates and low uptake [5]; and (B) in a sensitivity analysis where we excluded all persons 
known to have attained an SVR in Scotland, the TAF increased only marginally (by <5%; see eFig.4). Although, the 
same analysis was not performed for Denmark, we would expect an even slighter change here given lower treatment 
uptake rates, relative to Scotland. The second caveat is that some of our spontaneous resolvers will have been re-
infected during follow-up and will have then developed chronicity through that re-infection event. When conducting our 
sensitivity analysis, we noticed that 94 (2%) Scottish resolvers had been treated with antiviral therapy; these cases will 
reflect such instances of reinfection. This misclassification of resolver status is a limitation of our analysis; nevertheless, 
it will apply to a small fraction of cases only. Regarding the generalisability of these data: whilst we calculated TAFs 
13 
 
for two distinct North European countries and observed broadly similar results, we would not expect our findings to 
hold for all settings. In particular, we would anticipate a higher TAF overall in countries with an older infected 
population than Denmark and Scotland (and equally a lower TAF in countries with a younger infected population).  
Further our TAFs are unlikely to generalise to settings where HCV transmission is not associated with adverse health 
behaviours (in the main, low and some middle income countries where transmission is driven by nonsocomial routes as 
opposed to injecting drug use). Another limitation is that ~25-40% of diagnosis records were excluded from our final 
samples (mainly due to insufficient identifiers and missing chronic infection status) - we cannot rule out the 
introduction of selection bias into our results as a result of these exclusions. A further potential bias to note is that a 
physician may be more inclined to attribute a death to liver disease if the deceased had CHC infection as opposed to 
spontaneously resolved infection – if this is the case, then our TAFs will be biased towards one. We should further 
make clear that this analysis only examines the impact of CHC on liver sequalea and does not address the impact of 
CHC on extrahepatic outcomes and pyschosocial manifestations.  Finally, we did not use a consistent approach to 
determine injecting drug use history. In Denmark, IDU status was determined via a registry of drug abusers undergoing 
treatment, whereas in Scotland, IDU status is based on risk information disclosed to the physician at the time of the  
hepatitis C test. It is possible that the Danish definition (i.e. appearance on a drug abuse treatment register) will select 
out a more persistent subset of drug users that have been repeatedly exposed to HCV, and hence have a higher chance 
of chronicity. This might explain why an association between injecting drug use and chronic infection was observed for 
Denmark but not for Scotland (see Table 1). 
 
 
CONSISTENCY WITH PREVIOUS WORK: 
Our analysis suggests that a significant portion of liver mortality among CHC infected persons occurs independently of 
CHC infection. Previous work in resource-rich settings is in support of this, and points towards the non-CHC-
attributable death being a reflection of adverse health behaviours (AUDs in particular); as follows:
 
1. HCV infection is associated with a singular lifestyle profile, distinct from that of the general population [3, 7-
15].  
2. AUDs in particular are highly prevalent among persons with CHC [9-14] which are in turn strongly associated 
with liver mortality [46].  
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3. More than a third of Scottish CHC patients attending treatment services with liver cirrhosis, have reached this 
state as a direct consequence of heavy alcohol use [26]. Further, between 15 and 52% of liver deaths in this 
population are indicated directly, via the cause of death, to be a primary consequence of alcohol use. [5]. 
Indeed in this analysis, alcoholic liver disease was listed as the primary cause of death for 45% and 48% of 
liver deaths among CHC infected persons in Scotland and Denmark, respectively (see eFig.3).Thus, it is 
already known that that many instances of liver cirrhosis and liver mortality are attributable to alcohol use - but 
that is not to say that alcohol was the exclusive cause and that CHC did not contribute in a “necessary but 
insufficient” way). In this respect our results lend a distinct advancement, insofar as they indicate an 
appreciable fraction of liver death would still have occured in the absence of CHC.  
4. When HCV is introduced into cohorts with a stable lifestyle profile, rates of liver disease remain relatively low 
after 2-3 decades of infection [47-50]. 
5. Elevated mortality rates are also apparent in the siblings of HCV infected persons. These high rates mostly 
reflect an excess number of unnatural and substance abuse-related deaths. An excess number of liver deaths, 
albeit, was not observed [51, 52]. 
 
SUMMARY 
Most instances of liver mortality among CHC infected persons can be attributed to CHC – all the same, an appreciable 
fraction of liver death appears to be independent of this exposure. This suggests that antiviral therapy will only be a 
partial solution to the problem of wayward liver mortality in this population. A full solution should entail more 
emphasis on tackling adverse health behaviours and the circumstances that give rise to them. Recent data highlights that 
behavioural interventions might be effective in the HCV infected population [53]; but this historically has been (and so 
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FIG.1: Fraction of liver death attributable to chronic hepatitis C (CHC) according to age at death, in Denmark and 
Scotland. As a guide to interpretation, a total attributable fraction (TAF) of 0.00 would represent not attributable to 
CHC at all; a TAF of 0.50 would represent attributable to CHC and not attributable to CHC in equal parts; and a TAF 
of 1.00 would represent entirely attributable to CHC. 
 
